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Decreased Incidence of Viral Infections in 
Liver Transplant Recipients 
Possible Effects of FK506? 
NINA SINGH, MD, LUIS MIELES, MD, VICTOR L. YU, MD, THOMAS E. STARZL, MD, PhD 
Cytomegalovirus (CMV) is a major infectious complication of organ transplantation and 
its incidence is influenced by the type and intensity of immunosuppressive therapy 
employed. Using a new immunosuppressive agent FK506, CMV infection was observed in 
30% and CMV disease in 15% of the 26 liver transplant recipients. Delayed onset of CMV 
disease was noted; the mean time to the occurrence of CMV disease being 137 days 
posttransplantation. No graft loss or mortality could be. attributed to CMV infection. 
Mucocutaneous herpes simplex virus (HSV) infections were encountered in 19% of the 
patients, while no disease could be attributed to varicella zoster virus or Epstein-Barr 
virus (EBV). The contribution of FK506 to a decrease in viral morbidity and associated 
mortality bears further investigation. 
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CMV is a frequent source of morbidity and mortal-
ity after orthotopic liver transplantation (1, 2). The 
importance of immunosuppressive therapy in mod-
ulating the impact of CMV posttransplantation has 
previously been recognized (3). FK506 is a novel 
immunosuppressive agent that has been associated 
with less organ rejection and less early graft dys-
function (4). However, its impact on opportunistic 
viral infections is as yet uncertain. The newly es-
tablished liver transplantation program at the Pitts-
burgh VA Medical Center allowed prospective as-
sessment of consecutively transplanted patients 
receiving FK506 as primary immunosuppression. 
The purpose of this study was to evaluate the inci-
dence and clinical characteristics of viral infections, 
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in particular CMV infection in orthotopic liver 
transplant patients receiving FK506. 
MATERIALS AND METHODS 
Patient Population 
The study population comprised 26 consecutive adult 
male patients who underwent orthotopic liver transplants 
at the Pittsburgh VA Medical Center between November 
1989 and March 1991 and who survived at least 72 hr 
postoperatively. There were no exclusions. Their ages 
ranged between 28 and 65 years, with a mean of 46 years. 
Their diagnosis were cryptogenic cirrhosis (8), alcoholic 
cirrhosis (7), primary sclerosing cholangitis (5), non A, 
non B hepatitis (2), hepatitis B (2), primary biliary cirrho-
sis (1), and hemochromatosis (1). There was a total of 
three deaths. The duration of follow-up in the living 
patients ranged from 309 to 832 days, with a mean of 591 
days. 
Immunosuppression 
All patients received 0.10 mglkg of FK506 as a contin-
uous drip over 24 hr until able to take oral medications. 
The oral dosage of FK506 was 0.15 mglkg every 12 hr. 
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TABLE 1. INCIDENCE OF CMV INFECfION AND DISEASE IN LIVER TRANSPLANT RECIPIENTS 
Number of patients with 
PreopCMV Number of Infection Vual 
serology patients (%) syndrome 
Negative 5 2 (40) 1 
Positive 21 6 (28) 0 
Total 26 8 (30) 1 
Subsequent dosage adjustments were made as indicated 
by clinical course and FK506 plasma levels. One gram of 
methylprednisolone was given immediately after revascu-
larization of the graft. Twenty milligrams of methylpred-
nisolone was given intravenously immediately after trans-
plantation and daily thereafter until the oral route was 
established, at which time 20 mg of prednisone was ad-
ministered daily. During the subsequent months, predni-
sone was slowly tapered. 
Antiviral Prophylaxis. High-dose oral acyclovir in dos-
ages between 2400 to 3200 mg daily were used in three 
patients only. Four patients did not receive any acyclovir 
postoperatively. For the remaining 19 patients, the dos-
age of acyclovir ranged from 200 to 1600 mg daily. 
Definition of Viral Infections 
CMV Infection. CMV serology was determined using 
an enzyme immunosorbent assay (EIA) and titers ;:::0.79 
were considered positive. Primary infection was defined 
as isolation of virus or seroconversion in a patient who 
was seronegative before transplantation. Reactivation in-
fection was diagnosed by isolation of virus in a seropos-
itive recipient. 
CMV Disease. Clinical diseases caused by CMV were 
the following types: viral syndrome, localized CMV dis-
ease, and disseminated CMV disease. Viral syndrome 
due to CMV required the following: (1) positive culture 
for CMV, (2) fever 2:380 C with no other source to ac-
count for it; and (3) one of the following findings: a~pical 
lymphocytes ;:::3%; white blood count ::;4000/mm , and 
platelets::; 100,000/mm3 • Localized CMV disease was de-
fined as tissue invasion of a single organ determined 
histopathologically and by culture of the virus from tis-
sue. Disseminated disease was defined as tissue involve-
ment of two or more noncontiguous organ sites. 
EBV. Antibodies against viral capsid antigen, early 
antigen, and Epstein-Barr nuclear antigen were deter-
mined preoperatively in all patients. Patients were de-
fined as having a symptomatic EBV infection if they had 
EBV-associated lymphoproliferative disease by the pres-
ence of EBV DNA in tissue using nucleic acid hybridiza-
tion. Antibody titers to detect asymptomatic rise were not 
routinely determined. 
Herpes Simplex and Varicella Zoster. HSV infection 
was defined as presence of typical symptomatic oral or 
genital ulcers. For atypical lesions or those outside the 
genital or oral area, isolation of virus was also required. 
Varicella zoster virus infection was determined clinically 
by the presence of typical dermatomal lesions with or 
without viral isolation. 
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Total number 
Localized Disseminated of symptomatic 
CMV CMV patients (%) 
0 0 1 (20) 
2 1 3 (14) 
2 1 4 (15) 
RESULTS 
CMV Infection and Disease. Thirty percent (8/26) 
of patients developed CMV infection. These in-
cluded two (40%) of the five seronegative recipients 
and six (28%) of the 21 seropositive patients (Table 
1). Four of the eight infected patients were symp-
tomatic. These included one of the two recipients 
with primary infection who developed CMV viral 
syndrome that resolved spontaneously. Symptom-
atic disease was also diagnosed in three of six pa-
tients with reactivation CMV infection. CMV gas-
tritis (one patient), CMV retinitis (one patient), and 
disseminated CMV disease with hepatitis and colitis 
(one patient) were documented. All of these pa-
tients were treated successfully with ganciclovir. 
Timing of CMV Infection. CMV infection oc-
curred a mean of 80 days (range 23-225 days) after 
transplantation. Mean time to the onset of CMV 
disease was 137 days posttransplantation with a 
range of 65 to 220 days. Asymptomatic CMV shed-
ding in urine or buffy coat was detected in three of 
four patients who eventually developed CMV dis-
ease. The time interval between first detection of 
CMV and onset of overt CMV disease was 14 days 
in the patient with disseminated CMV, 42 days in 
the patient with gastritis, and 195 days in the patient 
with CMV retinitis. 
Relationship of CMV Infection to Recipient and 
Donor Antibody Status. Sixty-six percent (2/3) sero-
negative recipients with primary CMV infection re-
ceived livers from CMV -seropositive donors, 
whereas, 0% (0/2) seronegative recipients who re-
ceived livers from a CMV -seronegative 'donor de-
veloped CMV infection. 
No definite association was found between the 
occurrence of reactivation CMV infection and se-
rological status of the donor. The percentage of 
seropositive patients, 36% (4/11), who received liv-
ers from a CMV-seropositive donor was not signif-
icantly different from the percentage of patients, 
20% (2/10), who received livers from a seronegative 
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donor (P > 0.05). All patients received random 
blood products that were neither screened nor se-
lected for CMV antibody. 
Rejection Episodes. Thirty-five percent (9/26) of 
the patients did not have any rejection episodes. 
Another 35% (9/26) received methylprednisolone 
(l-g bolus per patient) for suspected, but not biop-
sy-proven rejection. The remaining 31 % (8/26) of 
patients had 10 episodes of biopsy-proven rejection. 
Of these 10 episodes, six were managed with ad-
justment of the baseline immunosuppression and 
four with a bolus of methylprednisolone, in addition 
to adjusting the baseline immunosuppression. No 
steroid recycles were given, and OKT3 was re-
quired in one patient only. 
Graft Loss and Mortality. Overall, 11% (3/26) of 
patients died within the study period. Deaths oc-
curred at 12, 25, and 42 days postoperatively. No 
evidence of CMV was present in patients who died. 
Likewise, none of the patients with CMV infection 
died. 
Twenty-six study patients underwent 29 ortho-
topic liver transplants. Second transplants in two 
patients were performed at four and six days post-
operatively, secondary to primary nonfunction of 
the transplanted allograft, and in the third patient 
616 days postoperatively due to chronic rejection. 
Graft loss was not attributable to CMV infection in 
any of the patients. 
Herpes Simplex. Nineteen percent (5/26) of pa-
tients experienced herpes simplex infections; all 
were mucocutaneous (orolabial) HSV infections. 
Mean time to onset was 82 days (range 10-223 days) 
postoperatively. Only one of the five patients with 
HSV infection was receiving acyclovir (200 mg ev-
ery day) at the time of occurrence of HSV infection. 
All patients responded to oral acyclovir (1000 mg 
every day) with no evidence of dissemination. 
Other Viral Infections. None of the patients de-
veloped varicella zoster infection or symptomatic 
EBV infection. Adenovirus was isolated from urine 
in an asymptomatic patient eight days postopera-
tively. 
DISCUSSION 
CMV has been recognized as the single most 
important contributor to posttransplant morbidity 
and mortality. Clinical presentation of CMV post-
operatively varies from asymptomatic infection to 
fulminant disease. It is important to differentiate 
between CMV infection and CMV disease. CMV 
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infection merely implies cultural or serologic evi-
dence of viral replication, whereas CMV disease 
indicates the presence of specific symptoms attrib-
utable to CMV pathogenicity confirmed by labora-
tory evidence. CMV infection has been reported in 
50-60% of the liver transplant recipients receiving 
cyclosporine, whereas clinically overt CMV disease 
is observed in 26-35% of the patients (1, 2, 5-7). 
The 15% incidence of CMV disease in our patients 
is the lowest reported in liver transplant recipients, 
to our knowledge. 
An important factor influencing the incidence and 
course of CMV infection posttransplantation is the 
type and intensity of the immunosuppressive regi-
men employed. Lower incidence of CMV infection 
has been reported with the cyclosporine-predni-
sone than with the azathioprine-prednisone combi-
nation (8, 9). The exact basis for the lower inci-
dence of CMV infection in our patients on FK506 
remains to be determined. A possible contributory 
variable is lower adjunctive immunosuppression 
with FK506. Steroid recycles for rejection were not 
required in any patient and only one patient re-
ceived OKT3 antibodies. A lower incidence of or-
gan rejection has been previously documented with 
FK506 as compared to other immunosuppressive 
regimens (10, 11), thereby obviating the need for 
high-dose corticosteroid and antilymphocyte ther-
apy. Both high-dose steroids and antilymphocyte 
preparations such as anti thymocyte globulin and 
OKT3 are associated with an increased risk of 
CMV-related disease (2, 12). The lower incidence of 
CMV infection and disease is unlikely to be due to 
acyclovir, as 89% of the patients did not receive the 
high dosages shown to be effective in kidney trans-
plants (13). 
A noteworthy finding was the relatively late oc-
currence of CMV disease in our patients. Mean 
time to the onset of CMV disease in our patients 
was 137 days; when CMV retinitis, which is typi-
cally a late-occurring disease, was excluded, the 
mean time to the occurrence of CMV disease was 
still 100 days. In prior studies virtually all CMV 
disease occurred within the first six to eight weeks 
posttransplantation (2, 5, 14). 
CMV disease is a significant contributor to graft 
loss and patient mortality. Prior to the introduction 
of ganciclovir, a mortality rate of 22% had been 
reported with CMV infection; the mortality with 
disseminated CMV disease being an astounding 
66% (2). Stratta et al reported decreased mortality 
(6%) from CMV in liver transplant recipients with 
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the routine use of ganciclovir (5). No graft loss or 
mortality could be attributed to CMV in our study. 
Fewer overall infections (15), lesser need for re-
transplantation due to rejection, and routine em-
ployment of ganciclovir for treatment of CMV dis-
ease are some of the contributory variables to 
decreased mortality. 
HSV infections were encountered in only 19% of 
the patients compared with 35% in cyclosporine 
patients in a previously reported study (2). The 
lower incidence may be due to oral acyclovir pro-
phylaxis and sparing use of OKT3 in the study 
population. OKT3 and other antilymphocyte prep-
arations have previously been associated with a 
higher incidence of symptomatic HSV infection (2, 
16). 
The results of this study must be interpreted with 
caution because of the relatively small sample size 
involved and the lack of concurrent controls. Nev-
ertheless, a comparison of patients receiving FK506 
from 1989 to 1991 with patients receiving cyclospor-
ine between 1985 to 1987 (2) showed a notably 
lower incidence of herpesvirus infections, CMV 
disease, and mortality attributable to viral infec-
tions. It is uncertain whether our findings reflect 
any unique characteristics of FK506 or less intense 
additive immunosuppression along with FK506 or a 
lower net immunosuppression associated with im-
proved technical and surgical standards. Given the 
recent introduction of FK506 into the transplant 
surgeon's armamentarium, these preliminary re-
sults appear highly promising and bear further in-
vestigation. 
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